A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Rifamycin (Primary)
- Indications Irritable bowel syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Cosmo Technologies
- 19 Nov 2018 Planned End Date changed from 28 Feb 2019 to 28 Feb 2020.
- 19 Nov 2018 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.
- 10 Apr 2018 The study has been changed from suspended to recruiting in Germany